3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
3
Status
Completed
2
Recruiting
1
Sponsor Class
OTHER
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Gastrointestinal
1
Breast
1
Conditions
Frailty
10
Neoplasms
7
Lymphoma
5
Breast Neoplasms
4
Prostatic Neoplasms
3
Lung Neoplasms
3
Lymphoma, Large B-Cell, Diffuse
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urogenital Neoplasms
1
Treatment Adherence and Compliance
1
Stomach Neoplasms
1
Solid Neoplasm
1
Sarcopenia
1
Sarcoma
1
Recurrence
1
Prostate Cancer Cured
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms, Plasma Cell
1
Myeloproliferative Disorders
1
Myelodysplastic Syndromes
1
Multiple Myeloma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
1
Leukemia, Myeloid, Acute
1
Kidney Neoplasms
1
Hepatic Malignancies
1
Interventions
Docetaxel
277
Prednisone
236
enzalutamide
175
Leuprolide
172
Radiotherapy
164
Abiraterone Acetate
153
Magnetic Resonance Spectroscopy
147
bicalutamide
137
Goserelin
134
Androgen Antagonists
111
Radiosurgery
101
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
100
apalutamide
78
abiraterone
75
gallium 68 PSMA-11
74
Specimen Handling
67
Gonadotropin-Releasing Hormone
58
darolutamide
56
Radiation
56
Triptorelin Pamoate
53
cabazitaxel
49
Zoledronic Acid
49
pembrolizumab
48
Radiotherapy, Intensity-Modulated
47
Flutamide
47
Brachytherapy
47
luprolide acetate gel depot
46
Standard of Care
45
Carboplatin
44
Estramustine
43
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Prostatic Neoplasms
×
Geriatric Assessment
×
Clear all
NCT06125145
2025-12-05
GAP
University of California, Davis
Phase NA
Completed
30 enrolled
NCT05582772
2025-07-03
TOPCOP3
University Health Network, Toronto
Phase NA
Recruiting
168 enrolled
NCT02876237
2018-05-31
PROGERAD
Institut Cancerologie de l'Ouest
Phase NA
Completed
230 enrolled